$72.40
+1.55 (+2.19%)
Open$71.17
Previous Close$70.85
Day High$74.40
Day Low$71.00
52W High$37.44
52W Low$21.27
Volume—
Avg Volume689.0K
Market Cap77.49M
P/E Ratio44.24
EPS$0.79
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
-38.1% upside
Current
$72.40
$72.40
Target
$44.79
$44.79
$31.89
$44.79 avg
$48.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 53.02M | 47.19M | 56.70M |
| Net Income | 1.91M | 1.39M | 1.91M |
| Profit Margin | 3.6% | 2.9% | 3.4% |
| EBITDA | 2.67M | 2.51M | 2.71M |
| Free Cash Flow | 1.24M | 802.3K | 1.02M |
| Rev Growth | +15.8% | -2.9% | 0.0% |
| Debt/Equity | 0.46 | 0.48 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |